betamethasone has been researched along with omeprazole in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bass, D; Pieroni, KP | 1 |
| AbuBakar, S; Appleton, D; Shu, MH; Zandi, K | 1 |
| Affuso, F; Bellavite, P; Fazio, S; McCullough, PA; Pandolfi, S; Zanolin, E | 1 |
13 other study(ies) available for betamethasone and omeprazole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Molecular characteristics for solid-state limited solubility.
Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Proton pump inhibitor treatment for congenital chloride diarrhea.
Topics: Adult; Amniotic Fluid; Betamethasone; Chloride-Bicarbonate Antiporters; Delivery, Obstetric; Diarrhea; Drug Therapy, Combination; Female; Humans; Hypothyroidism; Infant, Newborn; Magnetic Resonance Imaging; Metabolism, Inborn Errors; Omeprazole; Polyhydramnios; Pregnancy; Pregnancy Complications; Proton Pump Inhibitors; Thyroxine; Tocolysis; Treatment Outcome; Ultrasonography, Prenatal | 2011 |
Anti-inflammatory, gastroprotective and anti-ulcerogenic effects of red algae Gracilaria changii (Gracilariales, Rhodophyta) extract.
Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Betamethasone; Cell Line, Tumor; Chlorophyll; Dose-Response Relationship, Drug; Female; Gastric Juice; Gastric Mucosa; Gene Expression; Gracilaria; Humans; Hydrogen-Ion Concentration; Inflammation; Interleukin-6; Mucus; Omeprazole; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Stomach; Stomach Ulcer; Sulfhydryl Compounds; Tumor Necrosis Factor-alpha | 2013 |
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2
Topics: Aged; Aged, 80 and over; Aspirin; Betamethasone; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Dietary Supplements; Early Diagnosis; Female; Flavonoids; Follow-Up Studies; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Indomethacin; Italy; Male; Middle Aged; Omeprazole; Patient Acuity; Retrospective Studies; Risk Assessment; SARS-CoV-2; Time; Time-to-Treatment; Treatment Outcome | 2021 |